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Abstract: The marine-derived filamentous fungus Asteromyces cruciatus 763, obtained off 
the coast of La Jolla, San Diego, USA, yielded the new pentapeptide lajollamide A (1), along 
with the known compounds regiolone (2), hyalodendrin (3), gliovictin (4), 
1
N-norgliovicitin 
(5), and bis-N-norgliovictin (6). The planar structure of lajollamide A (1) was determined by 
Nuclear Magnetic Resonance (NMR) spectroscopy in combination with mass spectrometry. 
The absolute configuration of lajollamide A (1) was unambiguously solved by total 
synthesis which provided three additional diastereomers of 1 and also revealed that an 
unexpected acid-mediated partial racemization (2:1) of the L-leucine and L-N-Me-leucine 
residues occurred during the chemical degradation process. The biological activities of the 
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isolated metabolites, in particular their antimicrobial properties, were investigated in a series 
of assay systems. 
Keywords: fungus; Asteromyces cruciatus; cyclic peptides; OSMAC; total synthesis 
 
1. Introduction 
Filamentous fungi, particularly marine-derived fungi, are widely recognized as an emerging source 
for the production of novel and bioactive secondary metabolites [1–4]. This empirical fact is 
corroborated by the insights gained from recent fungal genome sequencing projects. These genomic 
studies attribute filamentous fungi an overall tremendous biosynthetic capacity because they commonly 
carry about 30 to 40 biosynthetic gene clusters coding for secondary metabolites [5,6]. However, the 
majority of these gene clusters have not yet been correlated to their corresponding natural products. 
Considering the given therapeutic value of fungal metabolites [1–4] and the huge amount of hitherto 
unexplored orphan and silent gene clusters, the activation and discovery of such biosynthetic loci 
represents a valuable strategy to obtain new bioactive products [7]. 
Filamentous fungi of the genus Asteromyces comprise currently only one valid species and  
belong to the division of mitosporic fungi [8]. To date, aside from triglycerides and sterols [9,10],  
only the compounds gliovictin (4) [9,11], 2,4-dimethyl-4,5-dihydrofuran-3-carbaldehyde, 
3S,5R-dihydrodimethylfuran-2-one, and cyclo-phenylalanine-serine [11] have been reported from 
different Asteromyces cruciatus samples. Fueled by the significantly high metabolic capacity of 
filamentous fungi and the fact that Asteromyces species are chemically underexplored, we performed a 
comprehensive chemical investigation with the strain Asteromyces cruciatus 763, obtained off La Jolla 
shore, San Diego, USA. In order to stimulate the production of secondary metabolites encoded by silent 
biosynthesis gene clusters and to enhance the production of constitutively produced secondary 
metabolites in our fungal isolate, we integrated the ―One Strain Many Compounds‖ (OSMAC)  
approach [12–15] into our study. In this paper, we report the isolation of a new pentapeptide designated 
lajollamide A (1), and four known 3R,6R configured epipolythiopiperazinedione antibiotics 
hyalodendrin (3) [16], gliovictin (4) [9,11,16–19], 1N-norgliovictin (5) [18] and bis-N-norgliovictin  
(6) [18–20], in addition to the phytotoxic naphthalenone regiolone (2) [21,22] (See Figure 1). The 
elucidation of the absolute configuration of 1 has been a challenging problem and we report here the 
results of these efforts. 
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Figure 1. Secondary metabolites isolated from Asteromyces cruciatus 763. 
 
2. Results and Discussion 
2.1. OSMAC Studies  
A panel of extracts was prepared under 14 different culture conditions (different media composition, 
changing cultivation periods, extraction procedures, UV-light exposure, and temperature) and screened 
by LC-MS. Two whole broth extracts of A. cruciatus 763, that were grown either in a Czapek-Dox 
medium supplemented with cofactors or in a Czapek-Dox medium with an altered nitrogen source, 
afforded a good variety of known metabolites (e.g., cyclo-phenylalanine-serine and gliovictin [9,11]) 
and previously unknown compounds (e.g., m/z [M + H]
+
 = 566). The HPLC profiles of these two 
extracts indicated that they contained almost the same metabolites but with significant differences in 
their relative concentrations. Thus, the two cultivation conditions were separately scaled up and 
processed to isolate and characterize the major metabolites present in each of these extracts.  
2.2. Isolation and Structure Elucidation 
The ethyl acetate extracts of the scaled-up fungal cultures were filtered through an RP-SPE cartridge 
and direct separation by RP-HPLC led to the isolation of compounds 1–6. While the identity of the 
known metabolites 2–6 was established by direct comparison of the [α]D, MS, 
1
H and 
13
C NMR data 
with literature data, for the new compound 1 a complete structure determination study was performed. 
Compound 1 was assigned the molecular formula C30H55N5O5 via HR-ESI-MS data (m/z 566.4280 
for [M + H]
+
), indicating a structure with six degrees of unsaturation. The IR spectrum showed 
absorption bands at 1633 cm
−1
, indicating the presence of amide functionalities. The 
1
H and 
13
C NMR 
spectra suggested that 1 was a peptide-type compound on the basis of chemical shifts and multiplicities 
typical for α-protons and carbons. In the 1H NMR spectrum, signals for five α-protons (δH 3.49, 4.23, 
4.47, 4.48, and 4.58), 4 NH protons (δH 6.21, 6.92, 7.27, and 7.42) and an N-methyl group (δH 3.29) were 
observed. Most other resonances were found in the upfield region, including those for both methylene 
and methine protons (δH 1.37–2.33) and ten doublet methyl resonances (δH 0.85–1.02). The 
13
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DEPT135 NMR spectra indicated 30 carbon resonances, consistent with the molecular formula derived 
from HR-ESI-MS, including five amide carbonyl carbons, ten methine carbons (five nitrogen-bearing), 
four methylene groups and eleven methyl groups (one nitrogen-bearing thereof) (Table 1). Interpretation 
of 1D and 2D NMR spectroscopic data of 1 allowed construction of five partial structures assigned as 
valine (Val), N-methylleucine (N-Me-Leu), and three leucine residues (Leu-1, Leu-2 and Leu-3). 
Resonances of each amino acid residue were identified by starting with an α carbon resonance in the 
region δC 50–65, locating the resonance of the α proton via the HSQC (Heteronuclear Single Quantum 
Coherence) spectrum, and using the COSY (Correlation Spectroscopy) spectrum to delineate the five 
independent spin systems formed by the respective amide and side chain protons of each amino acid. 
The resulting substructures were extended and corroborated by HMBC (Heteronuclear Multiple Bond 
Correlation) correlations (See Figure 2).  
Table 1. 
1
H and 
13
C NMR spectroscopic data for lajollamide A (1) 
a
. 
Unit Position δC 
b
 δH (mult, J in Hz) 
Leu-1 C=O 171.7, C  
α 53.6, CH 4.23, m 
β 40.7, CH2 1.56, m; 1.77, m 
γ 24.9, CH 1.54 m 
δ 23.0, CH3 
c
 0.94, d 
c
 
 21.3, CH3 
c
 0.90, d 
c
 
NH  6.21, brs 
Leu-2 C=O 172.5, C  
α 51.2, CH 4.48, m 
β 39.9, CH2 1.49, m; 1.86, m 
γ 25.2, CH 1.59, m 
δ 22.1, CH3 
c
 0.86, d 
c
 
 22.8, CH3 
c
 0.90, d 
c
 
NH  7.42, d (8.3) 
Leu-3 C=O 173.1, C  
α 50.1, CH 4.58, m 
β 37.2, CH2 1.48, m; 1.69, m 
γ 24.6, CH 1.51, m 
δ 23.2, CH3 
c
 0.92, d 
c
 
 21.9, CH3 
c
 0.88, d 
c
 
NH  7.27, m 
Val C=O 173.6, C  
α 55.3, C 4.48, m 
β 30.3, CH 1.89, m 
γ 18.5, CH3 0.94 
19.2, CH3 0.92 
NH  6.92, d (8.9) 
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Table 1. Cont. 
N-Me-Leu C=O 171.2, C  
α 65.2, CH 3.49, dd (4.1, 3.6) 
β 37.6, CH2 1.44, m; 2.24, m 
γ 25.3, CH 1.59, m 
δ 23.5, CH3 
c
 0.96, d 
c
 
21.7, CH3 
c
 0.97, d 
c
 
N-Me 40.9, CH3 3.29, s 
a
 Measured at 300 (
1
H) and 75 (
13
C) MHz in CDCl3; 
b
 Multiplicities were deduced from DEPT135 and HSQC 
experiments; 
c
 Assignments within a column may be interchanged. 
Figure 2. Key 
1
H–1H-COSY and 1H–13C-HMBC correlations leading to the identification of 
lajollamide A (1). 
 
The latter were key in the assignment of corresponding carbonyl groups, the γ-atoms of the leucine 
residues and the location of the N-methyl group. In this way, all resonances for each amino acid residue 
could be assigned apart from those for the Leu methyl groups, which could not be distinguished 
unambiguously from each other due to a heavy overlap of the methyl proton resonances. HMBC 
correlations from each NH/NCH3 resonance to one carbonyl carbon established the connectivity in the 
core of the structure (Figure 2): the NH signal of Leu-1 (δH 6.21) showed a long-range correlation  
to δC 171.2 which suggested that Leu-1 is connected to N-Me-Leu via its carbonyl group; further  
HMBC crosspeaks, this time between the signals of NH(Leu-2)/δC 171.7, NH(Leu-3)/δC 172.5,  
NH(Val)/δC 173.1 established the primary peptide sequence to be N-Me-Leu/Leu-1/Leu-2/Leu-3/Val. 
The ring closure was evident from 
1
H–13C couplings between the resonance of N-CH3 of N-Me-Leu and 
δC 173.6. These connectivities confirmed the cyclic pentapeptidic nature of 1, thereby satisfying the 
required six elements of unsaturation. Based on the origin of the source microorganism and on its 
peptidic structure, 1 was given the name lajollamide A. 
2.3. Initial Stereochemical Investigations 
To elucidate the configurations at the stereogenic centers of the amino acid moieties in 1, the natural 
product was fully hydrolyzed under acidic conditions. The hydrolysate obtained was analyzed by chiral 
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HPLC. The stereochemical identity of the hydrolyzed amino acids observed in the HPLC chromatogram 
(Figure 3) was established by comparison with the respective commercial authentic standards of known 
absolute configuration. This led to the identification of N-Me-L-Leu, L-Val and three Leu residues, two 
of which are bearing L- and one D-configuration. The position of the expected D-Leu residue within the 
peptide backbone, however, was not evident from this, nor from the NMR spectroscopic data. To clarify 
this unsolved question and thus to fully stereochemically characterize 1, we embarked on the total 
synthesis of the three possible diastereomers of this cyclic peptide. 
Figure 3. Stereochemical analysis of the amino acid building blocks in 1 by chiral HPLC 
after its acid-mediated hydrolysis. Selection of HPLC-UV traces used for assignments:  
(A) hydrolyzed lajollamide A (1, black), (B) L-Val (blue), (C) L-Leu (red), (D) D-Leu 
(green), and (E) N-Me-L/D-Leu (purple). 
 
2.4. Total Synthesis of Natural Lajollamide A (1) and of Its Diastereomeric Analogs B–D (7–9) 
In order to most efficiently access the three diastereomeric forms of lajollamide feasible based on the 
results of the peptide hydrolysis experiments, we chose a highly convergent synthetic approach applying 
solution phase peptide coupling chemistry. Retrosynthetically, the cyclic pentapeptide was divided into 
the three diastereomeric tripeptides 10a–c and the stereochemically defined dipeptide building block 11 
common to all target structures (Scheme 1). The latter can be derived of N-Boc-L-Val (12) and 
N-Boc-L-Leu (13). For the preparation of 10a and 10c, again a joint precursor dipeptide 14 could be 
defined, which is divergently transformable into the desired tripeptides by attaching N-Boc-L-Leu (13) 
or L-Leu-OMe (15) to its N- or C-terminus, respectively. The third fragment, 10b, is accessible from 
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D-Leu-OMe (18) and N-Boc-L-Leu-L-Leu-OMe (17). Dipeptides 14 and 17 are easily affordable from 
the commercially available amino acid precursors 13, 15 and 16. 
Scheme 1. Retrosynthetic analysis for the preparation of all possible lajollamide 
diastereomers bearing one D-Leu unit. 
 
The synthesis of the tri- (10a–c) and dipeptide (11) building blocks proceeded smoothly using 
standard peptide deprotection and coupling chemistry (Scheme 2): all peptide coupling steps were 
conducted using EDC and HOBt in CH2Cl2 with NEt3 as the base. Mild N-deprotection was achieved 
employing in-situ generation of HCl in MeOH by addition of acetylchloride. Saponification of the ester 
protective groups was generally carried out by applying 2 N NaOH in MeOH. Using these conditions, 
peptides 10a and 10c were prepared in three steps each, starting with 16 via dipeptide 14 in an overall 
yield of 62% and 54%, respectively. Analogously, 10b was accessible from 13 in 71% overall yield. For 
the preparation of the universal dipeptide precursor 11, N-Boc-L-Leu (13) was first dimethylated using 
MeI and NaH, with subsequent N-Boc removal to give 19. This compound was coupled to 12 by using 
EDC and HOBt in CH2Cl2 with DIPEA as the base and saponified to furnish 11 in 55% overall yield. 
Having all desired building blocks in hands, we started the assembly of the three lajollamide 
diastereomers (Scheme 3). After removal of the N-Boc group in 10a–c using 4N HCl in dioxane, 
coupling to 11 was again achieved with HOBt/EDC. The resulting fully protected pentapeptides 20a–c 
were saponified, activated by PFP-ester formation and directly cyclized by N-deprotection followed by 
in-situ addition of NEt3, leading to compounds 7–9. 
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Scheme 2. Synthesis of the tri- (10a–c) and dipeptide (11) building blocks of lajollamide A (1). 
a: HOBt, EDC, NEt3, CH2Cl2; b: AcCl, MeOH; c: 2N NaOH, MeOH; d: MeI, NaH, 
THF/DMF (10:1), 80 °C, 20 h; e: HOBt, EDC, DIPEA, CH2Cl2. 
 
Scheme 3. Assembly of the di- (11) and tripeptide (10a–c) building blocks to the target 
cyclopentapeptide structures 7–9. 
 
With the finalization of the synthesis of all anticipated lajollamide diastereomers 7–9, we started to 
compare the spectroscopic data of the authentic natural product with that of the synthetic material. To 
our surprise, however, none of the peptides 7–9 was identical to the natural compound. This was clearly 
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evident from substantial differences in chemical shifts in both 
1
H and 
13
C NMR spectra. For example, 
the chemical shifts of the amino acid α protons or the N-methyl groups differed significantly, as did all 
carbon chemical shifts, which was particularly apparent for the amide carbonyl signals (Figure 4). 
Figure 4. Comparison of selected signals in the 
1
H (left) and 
13
C (right) NMR spectra of 
natural lajollamide A (1, black), and compounds 7 (blue), 8 (green) and 9 (red). Shaded areas 
in the 
1H spectra show α protons (yellow) and N-methyl groups (grey). 
 
This unexpected outcome of our synthetic endeavors led us to revisit the initial analytical data of the 
fungal metabolite. While no ambiguities were found in the interpretation of the NMR data, a small peak 
with a retention time of ca. 38 min. in the HPLC chromatogram of the full hydrolysate of the natural 
product drew our attention (see Figure 3). In fact, based on comparison with authentic standards, this 
signal turned out to correspond to N-Me-D-Leu. As the planar structure of lajollamide only contains one 
N-Me-Leu moiety, which was assigned to be L-configured due to the large peak at ca. 27 min in our 
stereochemical analysis, the occurrence of a fraction of N-Me-D-Leu clearly indicated a partial 
epimerization of this unit during peptide hydrolysis. This led to the assumption that a similar 
racemization process can also be expected for the three other Leu building blocks present in the 
molecule. This opened the possibility of three L-Leu units initially being present in the natural product, 
which, assuming an epimerization rate of approx. 30% for each of these residues, would result in a 2:1 
ratio of L- to D-Leu in the analysis of the peptide hydrolysate, thus potentially explaining the 
spectroscopic differences of the natural product 1 when compared to the synthetic analogs 7–9. With 
these thoughts in mind, the preparation of a lajollamide diastereomer bearing L-configuration at all 
amino acids residues was undertaken. The synthesis of the respective all L-tripeptide precursor 10d 
followed the route depicted for the preparation of 10b as shown in Scheme 2, altered only by simply 
attaching L-Leu-OMe to the C-terminus of 17 in the second peptide coupling step. Compound 10d was 
obtained in overall 67% yield and further elaborated into the desired cyclic pentapeptide via all 
L-configured 20d according to the sequence depicted in Scheme 3. Due to the convergent nature of our 
synthetic approach, the preparation of the all L-configured lajollamide-type target molecule was thus 
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easily achieved with relatively little additional experimental work. To our great relief, this time, the 
analytical data for the synthetic material perfectly matched those of the natural product 1 (Figure 5). We 
thus unambiguously established the absolute configuration in natural 1, henceforth named lajollamide A, 
to be all L. The three stereochmically altered, purely synthetic analogs of 1 were consequently defined as 
lajollamides B–D (7–9). 
Figure 5. Comparison of the 
13
C (A) and 
1
H (B) NMR data of the isolated lajollamide A  
(1, black) with that of the identical, synthetically derived, all-L-configured material (red) 
a
. 
 
a
 Minor differences in the chemical shifts of the two NH protons between 6.6 and 6.8 ppm can be 
explained due to small differences in pH and/or concentration of the two NMR samples. 
2.5. Biological Activities of Compounds 1–9 
No cytotoxic or enzyme inhibitory activity was observed for compounds 1–9. In antibacterial assays, 
metabolites 2–5 were found to be inactive. However compounds 1, 7, 8 and 9 exhibited a weak 
antibacterial activity against Gram-positive bacteria at a concentration of 100 μM. The growth inhibition 
of Bacillus subtilis was 61%, 51%, 67%, and 41%, respectively. Pathogenic bacterial strains causing 
infectious diseases were also inhibited. Inhibition of Staphylococcus epidermidis was shown for 
compound 1 (30%), 7 (43%) and 8 (32%). Only compound 7 was active against methicillin-resistant 
Staphylococcus aureus (MRSA). Furthermore, in agar diffusion assays at the 50 μg level, potent 
antibacterial and antifungal properties towards Escherichia coli (2.5 mm total inhibition), Bacillus 
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megaterium (7 mm total inhibition), Mycotypha microspora (13.5 mm total inhibition), Eurotium 
rubrum (4 mm total inhibition), and Microbotryum violaceum (13 mm total inhibition) were 
demonstrated by 6, which in some cases surpassed the activity of the positive controls streptomycin, 
benzylpenicillin and miconazole.  
3. Experimental Section 
3.1. General Experimental Procedures 
Optical rotations were measured on a Jasco DIP 140 polarimeter. UV and IR spectra were obtained 
using Perkin-Elmer Lambda and Perkin-Elmer spectrum BX instruments, respectively. All NMR spectra 
of the isolated material were recorded on a Bruker Avance 300 DPX spectrometer. Spectra of the 
synthetic compounds were acquired on Bruker AM 300 and AM 400 spectrometers. Spectra were 
referenced to residual protonated solvent signals with resonances at δH/C 3.35/49.0 (CD3OD) or 
7.26/77.0 (CDCl3), respectively. HR-EI and HR-ESI-MS data was recorded on Kratos MS50, a Bruker 
Daltonics micrOTOF-Q and a Thermo Finnigan MAT 95 XL. Semipreparative HPLC was carried out 
using a Waters system consisting of a degasser, a 600 pump, a 996 photodiode array detector, and a  
717 plus autosampler in combination with a Waters fraction collector. Chiral HPLC was performed on a 
Merck-Hitachi system consisting of a L-6200 A pump, a L-4500 A photodiode array detector (PDA), 
and a D-6000 A interface. LC-MS measurements were obtained by employing an Applied Biosystems 
LC/MS system consisting of an Agilent 1100 HPLC system and an MDS Sciex API 2000 mass 
spectrometer equipped with an API-ESI source. All solvents used were distilled under argon and dried 
over 3 Å molecular sieves prior to use. All amino acids, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
(EDC), pentafluorophenol (PFP) were purchased from Carbolution Chemicals. 1-Hydroxybenzotriazole 
hydrate (HOBt∙H2O) was purchased from Aldrich, triethylamine (NEt3) from Grüssing GmbH and 
methyl iodide from Merck. Sodium hydride and 4N HCl/dioxane were delivered from Acros Organics. 
All chemicals were used without further purification. For thin layer chromatography TLC Silica gel 60 
F254 from Merck was used. The dyeing reagent consisted of ninhydrin in ethanol. For column 
chromatography, silica gel was purchased from Merck. 
3.2. Biological Material 
A piece of an unidentified decaying green alga, floating in the water column at a depth of 20 feet was 
collected by scuba in 2005 at La Jolla shore, San Diego, USA. Following transport in sterile seawater to 
Germany, the fungal strain #763 was isolated among other fungi from the algal sample, freed from 
competing microorganisms and other contaminants as previously described [23–25] and deposited at the 
fungal culture collection of the Institute for Pharmaceutical Biology, University of Bonn, Germany. The 
fungus was identified as Asteromyces cruciatus Moreau et Moreau ex Hennebert 1962.  
3.3. Screening of Secondary Metabolites Biosynthesized under Different Conditions (OSMAC Aproach) 
The OSMAC approach was based on cultures of the fungus in media derived from the basic 
components of the Czapek-Dox broth [26,27]: NaNO3 (3 g/L), FeSO4 (0.01 g/L), KCl (0.5 g/L), MgSO4 
(0.5 g/mL), K2HPO4 (1.0 g/L), carbon source (30 g/L, originally sucrose, however, when not indicated, 
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glucose was used) in artificial sea water (ASW). For the preparation of the culture medium, all 
components except the carbon source were mixed in 250 mL (1 L capacity, baffled Erlenmeyer flasks) 
of ASW and the mixtures were autoclaved (121 °C, 20 min). Subsequently, 20 mL of 40% (m/V) carbon 
source were added by sterile filtration to the medium, followed by inoculation with small pieces of seed 
culture. Small agar pieces (1 × 1 cm) of a 12–25-day-old culture of A. cruciatus grown on biomalt salt 
agar medium served as seed cultures. In order to find culture conditions conducive to production of new 
metabolites, two replicate cultures of A. cruciatus were grown in each of 14 different culture conditions: 
(#1) Czapek-Dox medium with shaking (#2) Czapek-Dox medium without shaking for generation of 
low O2 levels [28], (#3) dixenic cultivation [29] with 10 mL of the bacterium Pseudomonas fluorescens 
Pf-5 [30], added on day 6, (#4) Czapek-Dox medium containing 20 g/L Amberlite XAD-16,  
(#5) Czapek-Dox medium supplemented with 1 mL/L cofactor solution consisting of MnCl2·4H2O  
(100 mg), CoCl2 (20 mg), CuSO4 (10 mg), Na2MoO4·2H2O (10 mg), ZnCl2 (20 mg), LiCl (5 mg), 
SnCl2·2H2O (5 mg), H3BO3 (10 mg), K3BO3 (10 mg), KBr (20 mg), KI (20 mg), EDTA-Na
+
 (5.8 mg) in 
1 L of distilled water [28], (#6) Czapek-Dox supplemented with 4.6 mg/L CdCl2 as polyketide inducer [31], 
(#7) Czapek-Dox medium, cultivated from day 10 to 13 under elevated UV-B light exposition,  
(#8) Czapek-Dox medium, cultivated from day 8–10 at 35 °C [28], (#9) Czapek-Dox medium, 
cultivated with sub-inhibitory concentrations of 0.4 mL/L cycloheximide [32,33], (#10) Czapek-Dox 
medium, supplemented with 8 mL/L toluene, (#11) Czapek-Dox without NaNO3, containing 1.0 g/L 
Arg, 2.5 g/L Asn and 1.5 g/L Glu [28], (#12) Czapek-Dox with reduced levels of K2HPO4 (228.2 mg/L) 
for phosphate repression [28], (#13) Czapek-Dox medium without FeSO4 for induction of siderophores, 
(#14) Czapek-Dox medium with sucrose instead of glucose as carbon source [28]. If not stated 
otherwise, the cultures were grown with shaking (120 rpm) at 24 °C. The broth was harvested at 10 days 
after inoculation. The culture broths of each fermentation were extracted separately with EtOAc  
(2 × 250 mL), and evaporated under reduced pressure to afford dark brown semisolids, ranging from  
0.3 to 47.2 mg. In the case of culture condition #4, additionally the medium polarity compounds 
absorbed by the XAD resin material were eluted by shaking, first for 1 h in 200 mL EtOAc, and 
subsequently for 1 h in 200 mL acetone. All resulting three organic crude extracts of cultivation 
experiment #4 were combined. The resultant crude extracts of each experiment were dissolved in 
methanol to a final concentration of 5 mg/mL, and 10 μL was profiled by LC/MS using a 2 mM 
NH4OAc buffered MeOH/H2O gradient, increasing the MeOH portion from 10% to 100% over 20 min 
and holding it at 100% MeOH for additional 10 min (Macherey-Nagel C18 Nucleodur 100-5 column,  
2 × 125 mm, 5 μm column; 0.25 mL/min flow rate, with total ion current and photodiode array 
monitoring at 200–400 nm).  
3.4. Scaled-Up Cultivation, Extraction and Isolation of Metabolites of A. cruciatus 
The fungus was cultivated for ten days in five 5 L-Erlenmeyer flasks, each containing 1.5 L of liquid 
media (=7.5 L). The liquid medium consisted of Czapek-Dox medium with glucose (30 g/L) as carbon 
source which was either supplemented with co-factors or contained solely the amino acids Arg, Asn and 
Glu as nitrogen source instead of NaNO3. Flasks were shaken on a rotary shaker incubator at 24 °C and 
120 rpm. On day 10, the cultivation medium and mycelium of each experiment was extracted with 
EtOAc (2 × 7.5 L). After evaporation of the organic solvent, both crude extracts (medium with trace 
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elements: 126 mg; medium with an altered nitrogen source: 98 mg) were re-suspended separately in 
MeOH and filtered through reversed phase silica gel (RP-SPE cartridge, 100 mg). Separation of each 
filtrate by RP-HPLC analysis using a linear gradient of 40:60–100:0 MeOH-H2O over a period of  
54 min (column: Knauer Eurospher-100-C18; 8 × 250 mm, 5 μm; 2 mL/min; DAD detection) yielded 
collectively a compound (amount from trace element medium/amount from altered nitrogen source)  
1 (18.6/7.1 mg), 2 (0.9/0.7 mg), 3 (1.6/3.3 mg), 4 (19.8/19.4 mg), 5 (1.8/0.9 mg) and 6 (1.0/3.2 mg).  
lajollamide A (1): yellowish glass; [α]24
D
 −80 (c 0.17, MeOH); UV/VIS (MeOH) λmax (ε): 204 (12,600); 
IR (ATR): 3284, 2956, 1633, 1530 cm
−1
; HR-ESI-MS m/z 566.4280 [M + H]
+
 (calc. for C30H56N5O5, 
566.4276, Δ +0.7 ppm); 1H and 13C NMR data in CDCl3, see Table 1.  
regiolone, syn. (−)-isosclerone (2): Colorless film; [α]25
D
 −16 (c 0.02, MeOH), {lit. [21] [α]D −68 (c 0.05, 
MeOH)}; UV/VIS (MeOH) λmax (ε): 212 (15,800), 262 (9900), 324 (4200); 
1
H NMR (300 MHz, CDCl3) 
δH ppm: 1.87 (1H, brs, OH-4), 2.19 (1H, m, H-3a), 2.34 (1H, m, H-3b), 2.65 (1H, m, H-2a), 3.01 (1H, m, 
H-2b), 4.92 (1H, m, H-4), 6.93 (1H, d, 8.5 Hz, H-7), 7.02 (1H, d, 7.4 Hz, H-5), 7.50 (1H, dd, 7.4, 8.5 Hz, 
H-6), 12.43 (1H, s, OH-8); 
13
C NMR (75 MHz, CDCl3) δC ppm: 31.2 (CH2, C-3), 34.6 (CH2, C-2), 67.7 
(CH, C-4), 115.2 (qC, C-8a), 117.3 (CH, C-5), 117.8 (CH, C-7), 137.0 (CH, C-6), 145.8 (qC, C-4a), 
162.7 (qC, C-8), 204.2 (qC, C-1); LR-ESI-MS m/z 177.1 [M − H]−. 
(3R,6R)-hyalodendrin, syn. A26771A (3): Yellowish film; [α]24
D
 −71 (c 0.15, CHCl3) {lit. [16]  
[α]27
D
 −88 (c 0.15, MeOH)}; 1H NMR (300 MHz, CDCl3) δH ppm: 2.97 (3H, s, 
4
NCH3), 3.21 (3H, s, 
1
NCH3), 3.61 (1H, d, 16 Hz, H-8a), 4.08 (1H, d, 16 Hz, H-8b), 4.35 (2H, m, H2-7), 7.30 (5H, m, H-10, 
H-11, H-12, H-13, H-14); 
13
C NMR (75 MHz, CDCl3) δC ppm: 27.5 (
4
NCH3), 28.6 (
1
NCH3),  
36.8 (CH2, C-8), 61.2 (CH2, C-7), 75.2 (qC, C-6), 75.7 (qC, C-3), 127.4 (CH, C-12), 128.7 (2 × CH, 
H-10, H-14), 129.0 (2 × CH, H-11, H-13), 134.0 (qC, C-9), 165.5 (qC, C-2), 166.9 (qC, C-5); 
HR-ESI-MS m/z 347.0491 [M + Na]
+
 (calc. for C14H16N2NaO3S2, 347.0495, Δ −1.2 ppm). 
(3R,6R)-gliovictin, syn. A26771E, (3R,6R)-bisdethiodi(methylthio)hyalodendrin (4): Colorless 
film; [α]24
D
 −58 (c 0.88, CHCl3) {lit. [17] [α]
25
D
 −65 (CHCl3); [9] [α]D −62 (c 1.88, CHCl3); [16]  
[α]27
D
 −47 (c 0.13, CH3OH); [18] [α]
24
D
 −43 (c 0.24, CHCl3)}; 
1
H NMR (300 MHz, CDCl3) δH ppm: 
1.24 (1H, t, 6.9 Hz, OH-7), 2.13 (3H, s, 
6
SCH3), 2.30 (3H, s, 
3
SCH3), 3.02 (3H, s, 
4
NCH3), 3.10 (1H, 
dd, 6.9 and 11.8 Hz, H-7a), 3.13 (1H, d, 13.8 Hz, H-8a), 3.31 (3H, s, 
1
NCH3), 3.71 (1H, d, 13.8 Hz, 
H-8b), 3.85 (1H, dd, 6.9 and 11.8 Hz, H-7b), 7.09–7.27 (5H, m, H-10, H-11, H-12, H-13, H-14).  
13
C NMR (75 MHz, CDCl3) δC ppm: 13.4 (
6
SCH3), 14.3 (
3
SCH3), 29.3 (
1
NCH3), 31.0 (
4
NCH3),  
42.3 (CH2,C-8), 64.3 (CH2, C-7), 71.5 (qC, C-6), 73.7 (qC, C-3), 127.9 (CH-12), 128.7 (2 × CH, C-11 
and C-13), 130.1 (2 × CH, C-10 and C-14), 134.1 (qC, C-9), 165.3 (qC, C-2), 165.5 (qC, C-5); 
HR-ESI-MS m/z 377.0965 [M + Na]
+
 (calc. for C16H22N2NaO3S2, 377.0970, Δ −1.3 ppm). 
(3R,6R)-
1
N-norgliovictin, syn. bisdethiodi(methylthio)-1-demethylhyalodendrin (5): Colorless film; 
[α]24
D
 −37 (c 0.05, CH3OH) {lit. [18] [α]
24
D
 −63 (c 0.30, CHCl3)}; 
1
H NMR (300 MHz, CDCl3)  
δH ppm: 1.71 (1H, brs, OH-7); 2.19 (3H, s, 
3
SCH3), 2.22 (3H, s, 
6
SCH3), 2.71 (1H, d, 11.6 Hz, H-7a),  
3.15 (1H, d, 13.8 Hz, H-8a), 3.28 (3H, s, 
4
NCH3) , 3.41 (1H, d, 11.6 Hz, H-7b), 3.53 (1H, d, 13.8 Hz, 
H-8b), 6.36 (1H, brs, NH-1), 7.09–7.32 (5H, m, H-10, H-11, H-12, H-13, H-14); 13C NMR (75 MHz, 
CDCl3) δC ppm: 13.5 (
6
SCH3), 14.4 (
3
SCH3), 30.3 (
4
NCH3), 42.3 (CH2, C-8), 64.8 (qC, C-6),  
65.2 (CH2, C-7), 75.7 (qC, C-3), 128.0 (CH, C-12), 128.8 (2 × CH, C-10, C-14), 130.0 (2 × CH, C-11, 
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C-13), 133.7 (qC, C-9), 164.9 (2 × qC, C-2, C-5); HR-ESI-MS m/z 363.0818 [M + Na]
+
 (calc. for 
C15H20N2NaO3S2, 363.0813, Δ +1.4 ppm). 
(3R,6R)-bis-N-norgliovictin (6): [α]24
D
 −8 (c 0.1, CH3OH), {lit. [20] [α]D −32 (c 0.1, CH3OH); [18] 
[α]25
D
 −34 (c 0.30, dioxane)}; 1H NMR (300 MHz, CH3OD) δH ppm: 2.23 (3H, s, 
6
SCH3), 2.37 (3H, s, 
3
SCH3), 3.05 (H, d, 11.5 Hz, H-7a), 3.07 (1H, d, 13.3 Hz, H-8a), 3.40 (H, d, 11.5 Hz, H-7b), 3.62 (1H, 
d, 13.3 Hz, H-8b), 7.29 (5H, m, H-10, H-11, H-12, H-13, H-14); 
13
C NMR (75 MHz, CH3OD) δC ppm: 
13.5 (
3
SCH3 or 
6
SCH3), 13.9 (
3
SCH3 or 
6
SCH3), 46.0 (CH2, C-8), 66.5 (CH2, C-7), 67.8 (qC, C-3 or 
C-6), 68.8 (qC, C-3 or C-6), 128.4 (CH, C-12), 129.4 (2 × CH, C-11, C-13), 131.9 (2 × CH, C-10, 
C-14), 135.7 (qC, C-9), 167.8 (qC, C2 or C5), 168.2 (qC, C-2 or C-5); HR-ESI-MS m/z 349.0651  
[M + Na]
+
 (calc. for C14H18N2NaO3S2, 349.0657, Δ −1.7 ppm). 
3.5. Amino Acid Analysis by Chiral HPLC 
Lajollamide A (1.3 mg) was hydrolyzed with 6 N HCl in a sealed vial at 108 °C for 19 h. Excess 
aqueous HCl was removed under vacuum and the resulting hydrolysate was analyzed by chiral HPLC 
employing a Phenomenex Chirex 3126 (D) column (4.6 × 250 mm) eluting with 2 mM CuSO4/MeCN 
(95:5) at a flow of 0.8 mL/min, monitoring at 240 nm. Comparison with commercially available 
standards suggested the presence of L-Val, N-Me-L-Leu, 2 × L-Leu and 1 × D-Leu. The hydrolysate was 
chromatographed alone and co-injected with standards to confirm assignments. 
3.6. General Synthetic Protocols for the Preparation of Lajollamides A–D (1, 7–9) 
3.6.1. Peptide Coupling (Protocol A) 
The amine (1 equivalent) was dissolved in CH2Cl2. After cooling to 0 °C, the acid (1.1 equivalent), 
HOBt (1 equivalent), EDC (1.25 equivalent) and NEt3 (5 equivalent) were added successively to the 
solution. The reaction mixture was stirred at room temperature overnight. The solvent was removed 
under vacuum. The crude product was taken up in water and extracted with CH2Cl2. The organic layers 
were combined and washed successively with saturated aqueous NaHCO3 solution, 40% citric acid 
solution, brine and dried over MgSO4. The solvent was removed under reduced pressure and the crude 
product purified by column chromatography. 
3.6.2. N-Deprotection (Protocol B) 
3.6.2.1. Deprotection with Acetyl Chloride in Methanol 
N-Boc-protected peptide ester (1 equivalent) was dissolved in MeOH (24 equivalent). After cooling 
to 0 °C, acetyl chloride (2.2 equivalent) was added dropwise to the reaction solution which was further 
stirred at room temperature until completion of N-Boc removal as indicated by TLC. After solvent 
evaporation the crude product was taken up in CH2Cl2 and neutralized with saturated NaHCO3 solution. 
The aqueous layer was extracted with CH2Cl2. The organic layers were combined and dried over 
anhydrous MgSO4. After filtration the solvent was removed under high vacuum.  
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3.6.2.2. Deprotection with 4 M HCl∙Dioxane 
N-Boc-protected peptide ester (1 equivalent) was treated with 4 M HCl/dioxane (100 equivalent) 
under argon and stirred at room temperature for 1 h. The resulting reaction mixture was concentrated 
under high vacuum. 
3.6.3. Saponification (Protocol C) 
N-Boc-protected peptide ester (1 equivalent) was dissolved in MeOH (60 equivalent) und treated 
with 2 N NaOH (65 equivalent) solution. The reaction mixture was stirred at room temperature until the 
saponification finished as indicated by TLC. After solvent evaporation the crude product was taken up in 
CH2Cl2 and washed with H2O. The aqueous phase was acidified with 1 N HCl to pH 2 and extracted with 
CH2Cl2. The combined organic layers were dried over anhydrous MgSO4 and the solvent was removed 
under high vacuum.  
3.6.4. Macrolactonization (Protocol D) 
A fully protected pentapeptide (1 equivalent) was treated with 2 N NaOH following general protocol c. 
The resulting product was dissolved in CH2Cl2. After cooling to −10 °C EDC (1.3 equivalent), PFP  
(3 equivalent) and DMAP (0.1 equivalent) were added. The reaction mixture was stirred at room 
temperature overnight. After solvent evaporation and purification by column chromatography the 
resulting activated PFP ester was treated with 4 N HCl/dioxane (100 equivalent) following general 
protocol b2 to give the precursor for macrocyclisation. A highly dilute solution of the PFP ester  
(1 equivalent) in CH2Cl2 (0.003–0.01 M) was added dropwise to a solution of NEt3 (20 equivalent) in 
CH2Cl2. The resulting solution was stirred at room temperature overnight. After solvent evaporation the 
crude product was taken up in H2O and extracted with CH2Cl2. The combined organic layers were 
washed with 40% citric acid solution and brine and dried over anhydrous MgSO4. After filtration the 
solvent was removed under high vacuum.  
3.7. Total Synthesis of Lajollamides A–D (1, 7–9) 
3.7.1. N-Boc-L-Leu-L-Leu-OMe (17) 
Peptide coupling of 10.0 g (40.1 mmol) N-Boc-L-Leu (13) with 6.4 g (44.1 mmol) L-Leu-OMe (15) 
was conducted following general protocol a, yielding 12.2 g (34.1 mmol, 85%) of the desired product 17 
after chromatography on silica gel using ethylacetate and cyclohexane in 1:1 ratio as the eluent. 
1
H NMR 
(400 MHz, CDCl3) δH ppm: 0.85–0.98 (12H, m), 1.42 (9H, s), 1.51–1.65 (6H, m), 3.71 (3H, s), 4.09 (1H, 
brs), 4.59 (1H, m), 4.92 (1H, brs), 6.49 (1H, d, 6.5 Hz); 
13
C NMR (100 MHz, CDCl3) δC ppm: 21.8, 22.8, 
22.8, 24.6, 24.6, 24.7, 28.2, 40.8, 41.5, 50.6, 52.2, 52.9, 80.2, 155.6, 172.2, 173.1; ESI-MS m/z 381.2  
[M + Na]
+
, 281.2 [M + Na − C5H9NO2]
+
. 
3.7.2. N-Boc-D-Leu-L-Leu-OMe (14) 
Peptide coupling of 4.99 g (20.0 mmol) N-Boc-D-Leu (16) with 3.2 g (22.0 mmol) L-Leu-OMe (15) 
was conducted following general protocol a, yielding 6.3 g (17.6 mmol, 88%) of the desired product 14 
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after chromatography on silica gel using ethyl acetate and cylcohexane in 1:1 ratio as the eluent.  
1
H NMR (400 MHz, CDCl3) δH ppm: 0.87–0.95 (12H, m), 1.43 (9H, s), 1.51–1.65 (6H, m), 3.70 (3H, s), 
4.13 (1H, m), 4.57 (1H, m), 4.94 (1H, brs), 6.67 (1H, brs); 
13
C NMR (100 MHz, CDCl3) δC ppm: 21.9, 
22.9, 23.0, 24.8, 24.9, 24.9, 28.4, 41.1, 41.5, 50.8, 52.4, 53.1, 80.2, 155.8, 172.6, 173.4; ESI-MS m/z 
381.2 [M + Na]
+
, 281.2 [M + Na − C5H10N]
+
. 
3.7.3. N-Boc-D-Leu-L-Leu-L-Leu-OMe (10a) 
6 g (16.7 mmol) N-Boc-D-Leu-L-Leu-OMe (14) were saponified following general protocol c. The 
success of the deprotection step was monitored by 
1
H NMR of the resulting crude product (
1
H data for 
N-Boc-D-Leu-L-Leu: (400 MHz, CDCl3) δH ppm: 0.88–0.97 (12H, m), 1.41 (9H, s), 1.57–1.67 (6H, m), 
4.41 (1H, m), 4.60 (1H, m), 5.39 (1H, m), 7.11 (1H, brs), 10.55 (1H, brs)). This material was used in the 
peptide coupling step according to general protocol a with 2.1 g (14.8 mmol) L-Leu-OMe (15), yielding 
5.6 g (11.9 mmol, 71% overall) of the desired product 10a after chromatography on silica gel using 
ethylacetate and cyclohexane in 1:1 ratio as the eluent. 
1
H NMR (400 MHz, CDCl3) δH ppm: 0.85–0.95 
(18H, m), 1.42 (9H, s), 1.51–1.72 (9H, m), 3.70 (3H, s), 4.09 (1H, m), 4.47 (1H, m), 4.54 (1H, m), 4.97 
(1H, brs), 6.70 (1H, brs), 6.78 (1H, brs); 
13
C NMR (75 MHz, CDCl3) δC ppm: 21.9, 22.1, 22.1, 22.9, 
23.0, 24.7, 24.7, 24.8, 24.8, 28.4, 40.7, 41.1, 41.7, 50.8, 51.5, 52.2, 53.4, 80.0, 155.6, 171.9, 172.9, 
173.1; EI-MS m/z 456.3 [M − CH3], 440.3 [M − OCH3]
+
, 398.3 [M − C4H9O]
+
, 372.3 [M − Boc]+, 285.2  
[M − C10H20NO2]
+
, 259.2 [M − C13H27N2O3]
+
, 186.2 [M − C14H25N2O4]
+
. 
3.7.4. N-Boc-L-Leu-L-Leu-D-Leu-OMe (10b) 
2.6 g (7.3 mmol) N-Boc-L-Leu-L-Leu-OMe (17) were saponified following general protocol c. The 
success of the deprotection step was monitored by 
1
H NMR of the resulting crude product (
1
H data for 
N-Boc-L-Leu-L-Leu: (300 MHz, CDCl3) δH ppm: 0.86–0.99 (12H, m), 1.43 (9H, s), 1.58–1.73 (6H, m), 
3.93 (1H, m), 4.62 (1H, m), 5.40 (1H, d, 5.4 Hz), 6.79 (1H, d, 6.8 Hz), 9.03 (1H, brs)). This material was 
used in the peptide coupling step according to general protocol a with 1.11 g (7.7 mmol) D-Leu-OMe 
(18), yielding 2.9 g (6.15 mmol, 84% overall) of the desired product 10b after chromatography on silica 
gel using ethylacetate and cyclohexane in 1:1 ratio as the eluent. 
1
H NMR (400 MHz, CDCl3) δH ppm: 
0.88–0.97 (18H, m), 1.44 (9H, s), 1.49–1.78 (9H, m), 3.69 (3H, s), 4.04 (1H, m), 4.44–4.56 (2H, m), 
4.89 (1H, d, 6.7 Hz), 6.45 (1H, d, 6.5 Hz), 6.77 (1H, d, 6.8 Hz); 
13
C NMR (75 MHz, CDCl3) δC ppm: 
21.7, 21.8, 21.9, 22.1, 22.9, 22.9, 23.0, 24.8, 26.9, 28.3, 40.8, 40.9, 41.0, 50.8. 51.6, 52.1, 53.5,  
80.2, 156.0, 172.0, 172.8, 173.2; ESI-MS m/z 494.3 [M + Na]
+
, 438.3 [M + Na − C4H9]
+
, 394.3  
[M + Na − C4H9O]
+
. 
3.7.5. N-Boc-L-Leu-D-Leu-L-Leu-OMe (10c) 
3.09 g (8.62 mmol) N-Boc-D-Leu-L-Leu-OMe (14) were N-deprotected following general protocol 
b1. The success of the deprotection step was monitored by 
1
H NMR of the resulting crude product  
(
1
H data for D-Leu-L-Leu-OMe: (400 MHz, CDCl3) δH ppm: 0.86–0.95 (12H, m), 1.37 (2H, m),  
1.52–1.69 (6H, m), 3.38 (1H, m), 3.69 (3H, s), 4.57 (1H, m) 7.57 (1H, d, 7.6 Hz)). This material was 
used in the peptide coupling step according to general protocol a with 1.35 g (5.42 mmol) N-Boc-L-Leu 
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(13), yielding 2.5 g (5.30 mmol, 61% overall) of the desired product 10c after chromatography on silica 
gel using ethylacetate and cyclohexane in 1:1 ratio as the eluent. 
1
H NMR (400 MHz, CDCl3) δH ppm: 
0.88–0.98 (18H, m), 1.44 (9H, s), 1.49–1.76 (9H, m), 3.70 (3H, s), 4.07 (1H, m), 4.48 (1H, m), 4.54  
(1H, m), 4.86 (1H, m), 6.46 (1H, brs), 6.75 (1H, brs); 
13
C NMR NMR (75 MHz, CDCl3) δC ppm: 21.5, 
22.4, 22.6, 22.7, 23.0, 24.4, 24.4, 27.9, 29.3, 38.9, 39.9, 40.8, 41.5, 50.4, 51.8, 52.9, 55.6, 79.9, 155.3, 
171.4, 172.7, 175.6; ESI-MS m/z 494.3 [M + Na]
+
, 438.2 [M + Na − C4H9]
+
, 394.3 [M + Na − C4H9O]
+
. 
3.7.6. N-Boc-L-Leu-L-Leu-L-Leu-OMe (10d) 
6.51 g (18.17 mmol) N-Boc-L-Leu-L-Leu-OMe (17) were saponified following general protocol c. 
The success of the deprotection step was monitored by 
1
H NMR of the resulting crude product (
1
H data 
for N-Boc-L-Leu-L-Leu: see section 3.7.4. This material was used in the peptide coupling step according 
to general protocol a with 2.67 g (18.3 mmol) L-Leu-OMe (15), yielding 6.79 g (14.4 mmol, 79% overall) 
of the desired product 10d after chromatography on silica gel using ethylacetate and cyclohexane in 1:1 
ratio as the eluent. 
1
H NMR (400 MHz, CDCl3) δH ppm = 0.82–0.92 (18H, m), 1.39 (9H, s), 1.46–1.62 
(9H, m), 3.68 (3H,s), 4.11 (1H, m), 4.52 (2H, m), 5.24 (1H, m), 6.82 (1H, m), 7.00 (1H, m); 
13
C NMR 
(100 MHz, CDCl3) δC ppm: 21.9, 22.0, 22.3, 22.8, 22.9, 24.6, 24.7, 24.8, 24.8, 28.3, 41.01, 41.1, 41.3, 
50.7, 51.6, 52.2, 53.0, 79.9, 155.8, 171.9, 172.9, 173.2; ESI-MS m/z 965.5 [2M + Na]
+
, 494.3  
[M + Na]
+
, 394.3 [M + Na − Boc]+. 
3.7.7. N-Me-L-Leu-OMe (19) 
6 g (24.06 mmol, 1 equivalent) N-Boc-L-Leu (13) were dissolved in a mixture of THF and DMF in a 
10:1 ratio (198 mL) and treated with MeI (10 mL, 192.54 mmol, 8 equivalent). After cooling down to  
0 °C NaH (2.89 g, 72.20 mmol, 3 equivalent, 60% dispersion in oil) was added slowly to the reaction 
solution. The resulting mixture was stirred at 80 °C under reflux for 20 h. After removing the solvent  
in vacuo, the crude product was taken up in water (150 mL) and extracted with ethyl acetate (3 × 100 mL). 
The combined organic layers were washed with saturated NaHCO3 (2 × 100 mL) and H2O (3 × 100 mL) 
and dried over MgSO4. After solvent evaporation the desired product was purified via chromatography 
on silica gel using ethyl acetate and cyclohexane in 1:1 ratio as the eluent yielding 6.09 g (23.5 mmol, 
98%). Treatment of the resulting N-Boc-N-Me-L-Leu-OMe under conditions described in protocol B1 
furnished 3.61 g (22.7 mmol, 94% overall) of product 19. 
1
H NMR (300 MHz, CDCl3) δH ppm: 0.83 
(6H, m), 1.36–1.39 (3H, m), 1.57–1.64 (1H, m), 2.27 (3H, s), 3.11 (1H, m), 3.64 (3H, s); 13C NMR  
(75 MHz, CDCl3) δC ppm: 22.3, 22.6, 24.9, 34.6, 42.5, 51.5, 61.8, 176.2; ESI-MS m/z 182.1[M + Na]
+
, 
160.1 [M + H]
+
, 100.1 [M − CO2Me]
+
. 
3.7.8. N-Boc-L-Val-N-Me-L-Leu (11) 
1.40 g (8.80 mmol) N-Me-L-Leu-OMe (19) were dissolved in CH2Cl2 (40 mL) and HOBt, EDC and 
DIPEA were added successively to the solution which was stirred at 0 °C for 20 min. 1.95 g (9.96 mmol) 
N-Boc-L-Val (12) in CH2Cl2 (40 mL) was added to the reaction mixture and it was stirred at room 
temperature overnight. After quenching with saturated NH4Cl solution, the aqueous layer was extracted 
with CH2Cl2. The combined organic layers were washed with saturated NH4Cl solution and dried over 
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MgSO4. After solvent evaporation the product was purified via chromatography on silica gel using ethyl 
acetate and cyclohexane in 1:1 ratio, yielding 2.14 g (5.97 mmol, 68%) of the desired coupling product 
N-Boc-L-Val-N-Me-L-Leu-OMe. 
1
H NMR (300 MHz, CDCl3) δH ppm: 0.88–0.95 (12H, m), 1.41 (9H, s), 
1.62–1.71 (3H, m), 1.99 (1H, m), 3.00 (3H, s), 3.68 (3H, s), 4.41 (1H, m), 5.21 (1H, m), 5.36 (1H, m); 
13
C NMR (75 MHz, CDCl3) δC ppm: 17.7, 19.4, 21.5, 23.4, 24.8, 28,4, 29.8, 31.2, 37.1, 52.2, 54.5, 55.5, 
79.6, 156.1, 172.3, 173.6; ESI-MS m/z (%) = 381.3 [M + Na]
+
, 367.2 [M + Na − CH3]
+
, 281.2  
[M − C4H9O2]
+
. Saponification of the latter following protocol c delivered 1.8 g (5.13 mmol, 58% 
overall) of the dipeptide building block 11. 
1
H NMR (300 MHz, CDCl3) δH ppm: 0.88–0.98 (12H, m), 
1.41 (9H, s), 1.74 (3H, m), 1.99 (1H, m), 3.05 (3H, s), 4.41 (1H, m), 5.36 (1H, d, 5.2 Hz), 5.48 (1H, m), 
8.54 (1H, brs); 
13
C NMR (75 MHz, CDCl3) δC ppm: 17.9, 19.4, 21.5, 23.4, 24.8, 28.4, 29.8, 31.7, 37.0, 
54.8, 55.7, 79.7, 156.3, 174.3, 176.1; ESI-MS m/z 367.2 [M + Na]
+
, 353.2 [M + Na − CH3]
+
. 
3.7.9. N-Boc-L-Val-N-Me-L-Leu-D-Leu-L-Leu-L-Leu-OMe (20a) 
3.00 g (6.36 mmol) N-Boc-D-Leu-L-Leu-L-Leu-OMe (10a) were N-deprotected following general 
protocol b1. The success of the deprotection step was monitored by 
1
H NMR of the resulting crude 
product (
1
H data for D-Leu-L-Leu-L-Leu-OMe: (400 MHz, DMSO-d6) δH ppm: 0.82–0.89 (18H, m), 
1.23 (1H, m), 1.44–1.63 (8H, m), 3.22 (2H, m), 3.59 (3H, s), 3.22 (1H, m), 4.26 (1H, m), 4.45 (1H, m), 
8.01 (1H, m), 8.26 (1H, d, 8.3 Hz)). This material was used in the peptide coupling step according to 
general protocol a with 1.02 g (4.55 mmol) N-Boc-L-Val-N-Me-L-Leu (11), yielding 2.17 g (3.11 mmol, 
49% overall) of the desired product 20a after chromatography on silica gel using ethyl acetate and 
cyclohexane in 1:1 ratio as the eluent. ESI-MS m/z 720.4 [M + Na]
+
, 706.4 [M + Na − CH3]
+
. 
3.7.10. N-Boc-L-Val-N-Me-L-Leu-L-Leu-L-Leu-D-Leu-OMe (20b) 
3.51 g (7.44 mmol) N-Boc-L-Leu-L-Leu-D-Leu-OMe (10b) were N-deprotected following general 
protocol b1. The success of the deprotection step was monitored by 
1
H NMR of the resulting crude 
product (
1
H data for L-Leu-L-Leu-D-Leu-OMe: (400 MHz, CDCl3-d6) δH ppm: 0.88–0.98 (18H, m), 1.34 
(1H, m), 1.50–1.77 (8H, m), 3.46 (1H, m), 3.69 (3H, s), 4.44 (1H, m), 4.54 (1H, m), 6.80 (1H, d, 8.0 Hz), 
7.66 (1H, d, 8.4 Hz)). This material was used in the peptide coupling step according to general protocol 
a with 1.26 g (6.57 mmol) N-Boc-L-Val-N-Me-L-Leu (11), yielding 2.94 g (4.21 mmol, 57% overall) of 
the desired product 20b after chromatography on silica gel using ethyl acetate and cyclohexane in  
1:1 ratio as the eluent. ESI-MS m/z 720.5 [M + Na]
+
, 706.5 [M + Na − CH3]
+
, 370.2 [C19H36N3O4],  
327.2 [C17H32N2O4]
+
. 
3.7.11. N-Boc-L-Val-N-Me-L-Leu-L-Leu-D-Leu-L-Leu-OMe (20c) 
1.91 g (4.04 mmol) N-Boc-L-Leu-D-Leu-L-Leu-OMe (10c) were N-deprotected following general 
protocol b2. The success of the deprotection step was monitored by 
1
H NMR of the resulting crude 
product (
1
H data for L-Leu-D-Leu-L-Leu-OMe: (400 MHz, DMSO-d6) δH ppm: 0.81–0.90 (18H, m), 
1.45–1.71 (9H, m), 3.60 (3H, s), 3.82 (1H, m), 4.30 (1H, m), 4.37 (1H, m), 8.35 (2H, m), 8.52  
(1H, d, 8.5 Hz), 8.89 (1H, d, 8.9 Hz)). This material was used in the peptide coupling step according to 
general protocol a with 0.41 g (1.81 mmol) N-Boc-L-Val-N-Me-L-Leu (11), yielding 0.94 g (1.35 mmol, 
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33% overall) of the desired product 20c after chromatography on silica gel using ethyl acetate and 
cyclohexane in 1:1 ratio as the eluent. ESI-MS m/z 1418.0 [2M + Na]
+
, 720.5 [M + Na]
+
, 706.5  
[M + Na − CH3]
+
, 698.5 [M + H]
+
, 598.5 [M − Boc − H]+, 553.4 [M − C7H14NO2]
+
, 440.3  
[M − C13H25N2O3]
+
, 327.2 [M − C19H36N3O4], 370.2 [C19H36N3O4]. 
3.7.12. N-Boc-L-Val-N-Me-L-Leu-L-Leu-L-Leu-L-Leu-OMe (20d) 
3.99 g (8.46 mmol) N-Boc-L-Leu-L-Leu-L-Leu-OMe (10d) were N-deprotected following general 
protocol b2. The success of the deprotection step was monitored by 
1
H NMR of the resulting crude 
product (
1
H data for L-Leu-L-Leu-L-Leu-OMe: (400 MHz, DMSO-d6) δH ppm: 0.81–0.93 (18H, m), 
1.46–1.66 (9H, m), 3.60 (3H, s), 3.77 (1H, m), 4.30 (1H, m), 4.41 (1H, m), 8.28 (2H, brs), 8.45 (1H, d, 
7.8 Hz), 8.67 (1H, d, 8.3 Hz)). This material was used in the peptide coupling step according to general 
protocol a with 2.75 g (12.26 mmol) N-Boc-L-Val-N-Me-L-Leu (11), yielding 4.5 g (6.45 mmol, 76% 
overall) of the desired product 20d after chromatography on silica gel using ethyl acetate and 
cyclohexane in 1:1 ratio as the eluent. ESI-MS m/z 720.6 [M + Na]
+
, 706.5 [M + Na − CH3]
+
. 
3.7.13. Lajollamide B (7) 
1.79 mg (2.56 mmol) N-Boc-L-Val-N-Me-L-Leu-D-Leu-L-Leu-L-Leu-OMe (20a) were saponified 
following general protocol c. The resulting product was dissolved in CH2Cl2 and PFP, EDC and DMAP 
were added following general protocol d. After the N-deprotection following general protocol b2 the 
resulting crude product was further used without further purification. A solution of 1.62 g (2.06 mmol) 
of the linear precursor in CH2Cl2 (350 mL) and a solution of NEt3 (4.7 mL, 33.6 mmol) in CH2Cl2  
(240 mL) were conducted following general protocol d, yielding 0.94 g (1.66 mmol, 65% overall) of 
lajollamide B. 
1
H NMR (300 MHz, CDCl3) δH ppm: 0.90–0.98 (30H, m), 1.42–1.63 (6H, m), 1.70 (6H, 
m), 2.28 (1H, m), 2.86 (3H, s), 3.33 (1H, brs), 4.31 (1H, m), 4.47 (1H, m), 4.63 (1H, m), 4.70 (1H, m), 
5.00 (1H, m), 7.08 (1H, brs), 8.00 (1H, brs), 8.30 (1H, brs); 
13
C NMR (300 MHz, CDCl3) δC ppm: 18.8, 
19.7, 21.8, 22.4, 22.6, 22.7, 22.9, 23.1, 23.3, 23.4, 24.9, 25.1, 25.2, 25.5, 29.8, 36.7, 37.7, 39.7, 39.9, 
43.2, 50.8, 51.4, 54.0, 54.1, 58.2, 168.5, 171.5, 171.9, 172.6, 173.9; ESI-MS m/z 588.4 [M + Na]
+
, 574.4 
[M + Na − CH3]
+
, 560.4 [M + Na − C4H16]
+
. 
3.7.14. Lajollamide C (8) 
270 mg (0.39 mmol) of N-Boc-L-Val-N-Me-L-Leu-L-Leu-L-Leu-D-Leu-OMe (20b) were saponified 
following general protocol c. The resulting product was dissolved in CH2Cl2 and PFP, EDC and DMAP 
were conducted following general protocol d. After N-deprotection following protocol b2 the resulting 
crude product was used without further purification. A solution of 180 mg (0.23 mmol) of the linear 
precursor in CH2Cl2 (80 mL) and a solution of NEt3 (0.6 mL, 4.58 mmol) in CH2Cl2 (25 mL) were 
conducted following general protocol d, yielding 120 mg (0.012 mmol, 54% overall) of lajollamide C. 
1
H NMR (400 MHz, CDCl3) δH ppm: 0.88–0.97 (30H, m), 1.46–1.76 (12H, m), 2.00 (1H, m), 3.13 (3H, 
brs), 4.36 (1H, m), 4.47 (1H, m), 4.58–4.63 (2H, m), 4.79 (1H, m), 6.72 (1H, brs), 7.01 (2H, brs), 7.43 
(1H, brs); 
13
C NMR (400 MHz, CDCl3) δC ppm: 18.7, 19.2, 21.8, 22.4, 22.4, 22.5, 22.8, 22.8, 23.0, 23.1, 
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25.0, 25.1, 25.2, 25.3, 31.0, 31.5, 37.1, 38.2, 40.3, 41.4, 51.0, 52.2, 53.0, 55.3, 55.6, 170.5, 171.7, 172.0, 
172.2, 174.4; ESI-MS m/z 588.4 [M + Na]
+
, 566.4 [M + H]
+
. 
3.7.15. Lajollamide D (9) 
0.19 g (0.27 mmol) of N-Boc-L-Val-N-Me-L-Leu-L-Leu-D-Leu-L-Leu-OMe (20c) were saponified 
following general protocol c, yielding 0.14 g (0.20 mmol, 75%) of the desired product. This was 
dissolved in CH2Cl2 and PFP, EDC and DMAP were conducted following general protocol d. After 
N-deprotection the following general protocol b2 resulting crude product was used without further 
purification. 80 mg (0.11 mmol) of the linear precursor in CH2Cl2 (37 mL) and a solution of NEt3  
(0.3 mL, 2.13 mmol) in CH2Cl2 (12.5 mL) were conducted following general protocol d, yielding 40 mg 
(0.07 mmol, 26% overall) of lajollamide D. 
1
H NMR (300 MHz, CDCl3) δH ppm: 0.86–0.94 (30H, m), 
1.50–1.86 (12H, m), 2.13 (1H, m), 3.03 (3H, s), 3.51 (1H, m), 4.20 (2H, m), 4.47 (2H, m), 6.42 (1H, brs), 
6.58 (1H, brs), 7.10 (1H, brs), 8.19 (1H, d, 8.2 Hz); 
13
C NMR (300 MHz, CDCl3) δC ppm: 18.1, 19.9, 
21.3, 22.0, 22.4, 22.4, 22.7, 22.8, 23.0, 23.3, 24.9, 25.0, 25.4, 25.8, 30.5, 38.4, 39.6, 40.0, 40.1, 41.0, 
51.1, 52.8, 54.2, 55.9, 70.3, 171.7, 171.9, 172.0, 172.7, 173.4; ESI-MS m/z 588.4 [M + Na]
+
, 574.4  
[M + Na − CH3]
+
, 560.4 [M + Na − C4H16]
+
. 
3.7.16. Lajollamide A (1) 
4.5 g (6.45 mmol) of N-Boc-L-Val-N-Me-L-Leu-L-Leu-L-Leu-L-Leu-OMe (20d) was saponified 
following the general protocol c. The resulting product was dissolved in CH2Cl2 and PFP, EDC and 
DMAP were added following the general procedure d. After N-deprotection following protocol b2 the 
resulting crude product was used without further purification. A solution of 4g (5.09 mmol) of the linear 
precursor in CH2Cl2 (500 mL) and a solution of NEt3 (14 mL, 101.74 mmol) in CH2Cl2 (200 mL) were 
conducted following general protocol d, yielding 1.73 g (3.06 mmol, 47% overall) of lajollamide A.  
1
H NMR (400 MHz, CDCl3) δH ppm: 0.88–1.00 (30H, m), 1.51–1.64 (9H, m), 1.89 (3H, m), 2.22 (1H, 
m), 3.36 (3H, s), 3.51 (1H, brs), 4.25 (1H, m), 4.47 (1H, m), 4.58 (2H, m), 6.04 (1H, brs), 6.65 (1H, brs), 
6.84 (1H, brs), 7.38 (1H, brs); 
13
C NMR (300 MHz, CDCl3) δC ppm: 18.6, 19.3, 21.4, 21.9, 22.1, 22.4, 
22.8, 23.0, 23.4, 23.6, 24.8, 25.1, 25.4, 25.5, 30.4, 37.2, 37.6, 40.1, 40.8, 41.1, 50.4, 51.4, 53.9, 55.5, 
65.3, 171.6, 172.2, 172.7, 173.3, 173.9; ESI-MS m/z 588.4 [M + Na]
+
, 566.4 [M + H]
+
. 
3.8. Biological Activity 
The antimicrobial activities of compounds 1, 7, 8 and 9 were determined as previously described [34] 
using the following indicator strains: Candida albicans (DSM 1386), Bacillus subtilis (DSM 347),  
E. coli K12 (DSM 498), Xanthomonas campestris (DSM 2405), Staphylococcus epidermidis (DSM 
20044) and methicillin-resistant Staphylococcus aureus (MRSA) (DSM 18827). Furthermore, the 
compounds were tested for inhibition of phosphodiesterase (PDE4-4B2) and cytotoxicity to HepG2 
(human hepatocellular carcinoma) cells. The determination of the acetylcholinesterase inhibitory 
activity was performed according to Ohlendorf et al. (2012) [35]. Glycogen synthase kinase-3β 
inhibition was determined as described by Baki et al. (2007) [36]. The activity of compounds 4 and 6 
was tested in agar diffusion assays against the bacteria Escherichia coli and Bacillus megaterium, the 
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fungi Microbotryum violoaceum, Eurotium repens and Mycothypha microsporum, and the green 
microalga Chlorella fusca, as previously described [37]. Benzylpenicillin (6 mm growth inhibition 
towards Bacillus megaterium) and streptomycin (5 mm and 10 mm total inhibition towards  
Escherichia coli and Bacillus megaterium, respectively) were used as positive control for the 
antibacterial agar diffusion assays. In antifungal and antialgal assays, miconazole served as a positive 
control, resulting in total inhibition zones of 6–10 mm.  
4. Conclusions  
In this paper we described the isolation and full structural characterization of the antibacterial marine 
fungus-derived cyclopentapeptide lajollamide A (1). Stereochemical investigations were successfully 
completed by total synthesis of 1, along with three unnatural congeners, lajollamides B–D (7–9). The 
unexpected epimerization of Leu units in the lajollamide framework observed during our studies clearly 
demonstrates the danger in misassigning natural product structures elucidated by spectroscopic methods 
and relatively harsh analytical techniques alone. This demonstrates the importance of total synthesis for 
the unambiguous structural assignment of new molecules.  
It is interesting to note that cyclopentapeptides structurally related to lajollamide A (1)  
seem to be widespread among fungal strains. Examples include the cytotoxic sansalvamide 
[cyclo-(O-Leu-Val-Leu-Phe-Leu)] from a marine Fusarium strain [38], a cyclic pentapeptide recently 
isolated by Laatsch and coworkers [cyclo-(Ile-Leu-Leu-Leu-Leu)] from an endophytic fungus 
Cryptosporiopsis sp. [39], and a compound described by Li et al. [cyclo-(Phe-Leu-Leu-Leu-Leu)] [40] 
These metabolites share a Leu-rich backbone incorporating one or two differing amino acids with 
likewise hydrophobic (Val, Ile) or aromatic (Phe) side-chains. In addition, similar compounds can also 
be found in bacteria, e.g., the game-X-peptides [e.g., cyclo-(L-Leu-D-Phe-D-Leu-Leu-D-Val)] from 
Photorhabdus luminescens, albeit with D-configured amino acids being incorporated into these 
compounds via their NRPS-mediated biosynthesis [41]. The broad occurrence of such peptides clearly 
raises as yet unanswered questions about their true function and importance in ecological systems. 
Besides the characterization of lajollamide A (1), this work provided further insights into the 
secondary metabolome of an underexplored marine fungal isolate Asteromyces cruciatus. This organism 
proved capable of producing a series of other biomedically interesting natural products, compounds 2–6. 
The biological properties of all isolated compounds were investigated in a series of assay systems, 
revealing the lack of any cytotoxic or enzyme inhibitory activities in the biological tests used, but 
antibiotic properties of 1 and 6–9. The work presented here thus expands the small number of 
biomedically interesting metabolites known from A. cruciatus and further demonstrates the high 
potential of marine fungi for the production of diverse biologically active small molecules. 
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